Inhibitor Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013 - 1996
Net Income	-3.03	12.11	-0.31	-1.06	-2.72	-4.55	-5.1	-7	-3.95	-3.98	Upgrade
Share-Based Compensation	0.01	0	0.04	0.23	0.27	0.54	1.87	3.56	1.72	0.75	Upgrade
Other Operating Activities	0.31	-0.37	0.06	0	-0.26	0.3	0.32	-0.32	-0.04	1.92	Upgrade
Operating Cash Flow	-2.7	11.74	-0.22	-0.83	-2.71	-3.71	-2.91	-3.76	-2.26	-1.3	Upgrade
Dividends Paid	0	-0.19	-0.1	-0.1	-0.1	-0.06	0	0	0	-1.02	Upgrade
Common Stock Issued	0	0	0.2	0.2	0.1	3.96	-3.68	5.5	2.5	1.5	Upgrade
Share Repurchases	0	0	-0.18	-0.1	0	0	0	0	0	1.02	Upgrade
Other Financing Activities	-0.41	0.37	-0.1	-0.1	2.4	0.57	0.05	4.54	-	2.21	Upgrade
Financing Cash Flow	-0.41	0.18	0.18	0.1	2.4	4.47	-3.63	10.04	2.5	1.67	Upgrade
Net Cash Flow	-3.11	11.92	-0.04	-0.73	-0.3	0.76	-6.54	6.28	0.24	0.36	Upgrade
Free Cash Flow	-2.7	11.74	-0.22	-0.83	-2.71	-3.71	-2.91	-3.76	-2.26	-1.3	Upgrade
Free Cash Flow Per Share	-0.02	0.03	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01	-0.01	-0.01	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.